Pulmonary exacerbation inflammatory phenotypes in adults with cystic fibrosis

Background: Adults with cystic fibrosis (CF) develop exuberant inflammatory responses during pulmonary exacerbations (PEx) but whether distinct systemic inflammatory profiles can be identified and whether these associate with disparate treatment outcomes are unclear. We conducted a pilot study to address this question and hypothesized that CF adults with a pauci-inflammatory phenotype might derive less clinical benefit from intravenous (IV) antibiotic treatment than patients with other systemic inflammatory phenotypes.Methods: Six proteins reflective of systemic inflammation were examined in 37 PEx from 28 unique CF subjects. We applied exploratory factor analysis and cluster analysis to identify biological clusters. Levels of blood proteins at PEx and clinical outcomes following IV antibiotic treatment were compared between clusters.Results: Three clusters of PEx were identified. The pauci-inflammatory phenotype was characterized by lower levels of interleukin (IL)-1 beta, IL-6, IL-10, tumor necrosis factor (TNF)-alpha, calprotectin, and C-reactive protein (CRP) (p < 0.05). Higher levels of IL-6 and IL-1 beta were observed in the other 2 inflammatory clus-ters, but one of them was associated with higher calprotectin levels (p = 0.001) (neutrophil-predominant phenotype); whereas the other was associated with increased TNF-alpha and IL-10 levels (p < 0.001) (pro-inflammatory phenotype). A greater proportion of events from the neutrophil-predominant phenotype presented with acute respiratory symptoms and a larger decrease in ppFEV1 from baseline to hospital admission than the other two inflammatory phenotypes (p = 0.03).Conclusions: Three distinct inflammatory phenotypes were identified at PEx admission and each pre-sented with unique clinical characteristics.(c) 2022 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.